Advance Precision Medicine, Drug Development & Gene Therapy Approaches for More Curative Treatment of Heart Failure & Rare Cardiomyopathies

Join Us in Boston Right Now!

You can still register to join this meeting in Boston across today and tomorrow

Welcome to the 2nd HFpEF & HCM Drug Discovery & Development Summit

The Industry's Only Definitive Forum for Cardiovascular Drug Discovery & Development

As BioCardia’s off-the shelf cell therapy for HFpEF enters first-in-human study and AstraZeneca meets its primary endpoint in phase III, bipharma are racing to bring disease-modifying therapies to the world’s biggest killer.

Uniting industry leaders from Pfizer, Eli Lilly, Regeneron, Bayer and more, the 2nd HFpEF & HCM Drug Discovery & Development Summit is dedicated to redefining the new standard of care with precision medicine and regenerative therapies.

Join the exclusive forum dedicated to interrogating the latest progress in precision cardiology, implementing gene therapy, and constructing cost-effective phase II trials with multiple endpoints in interconnected organ systems.

With more speakers, more content on wider cardiomyopathies including amyloidosis, HCM, and Duchenne’s, and a greater focus on networking than ever before, do not miss this opportunity to get market intelligence from the commercially important and growing, cardiovascular R&D field.

World-Class Speaker Faculty Includes:

Check out what some of our speakers have to say:

Javed Butler

"I look forward to discussing the historical evolution in thinking about the syndrome of HFpEF and the pitfalls of continuing to think in a traditional paradigm"

Javed Butler, Director of Cardiovascular Medicine, Stony Brook Medicine

"The opportunity to meet and discuss a topic as complex as HFpEF in a dedicated meeting with ample time and with a common goal does not come often and is highly appreciated."

Ola Vedin, Global Medical Director, Heart Failure, Boehringer Ingelheim

Ola Vedin
Rachel Roth Flach

"Developing a deeper understanding of mechanisms underlying HFpEF for development of novel therapeutics that may combat this disease."

Rachel Roth Flach, Senior Principle Scientist, Pfizer

Our Partners:

nordic (1)
OM1_Logo
AnaBios logo
Antaros Medical AB
logo-physiogenex

Other Events in the Series

HW220901 5th CKD Summit logo
HW220619 25586 6th Obesity & NASH Drug Development Summit NEW COLOURS FINAL